Thrombosis in conversation

Episode 11: Real-world evidence: Anticoagulation strategies for CAT

“There’s no doubt that pharmacological prophylaxis is under used.” Dr Carrier and Dr Barnes discuss the real-world evidence underpinning strategy for the management of CAT.

Episode 10: Cancer heterogeneity and CAT

Dr Marc Carrier and Dr Barnes discuss the challenges posed by cancer heterogeneity when managing CAT.

Episode 9: Unmet medical needs in AF management

Dr Proietti and Professor Lip highlight unmet needs in AF management for stroke prevention and their prevalence among people with AF.

Episode 8: Real-world evidence for managing AF in stroke prevention

Can real-world evidence improve treatment selection and individualised care for AF in stroke prevention? Dr Proietti and Professor Lip discuss.

Episode 7: AF screening and detection technologies in stroke prevention

“Wearable technologies for stroke prevention are an exciting trend in the field” Dr Proietti and Professor Lip examine the benefits and disadvantages of wearable technologies for AF screening and detection in stroke prevention.

Episode 6: Treatments and guideline recommendations for managing CAT

Dr Rajasekhar and Dr Barnes consider treatment selection for CAT, highlighting the role of warfarin, and discuss optimal treatment length and the use of IVC filters according to current guidelines.

Episode 5: Assessment and guideline recommendations for recurrent VTE in patients without cancer

“Why did a patient get their blood clot in the first place, and how does that influence our decisions?” Dr Barnes is joined by Dr Anita Rajasekhar for a discussion of the causes and risk factors of VTE in people without cancer, and the relationship of risk and cause with treatment selection. With reference to clinical guidance, Dr Rajasekhar talks about diagnosis of recurrent VTE in the clinical setting and the importance of patient preference.

Episode 4: Management of challenging CAT and anticoagulation

Dr Deborah Siegal and Dr Barnes discuss thrombocytopenia and its treatment, including anticoagulation therapy and the inferior vena cava (IVC) filter, and touch on the challenge of balancing bleeding risk with VTE recurrence in people with brain tumours.

Episode 3: Real-world evidence for VTE

“How do we apply [clinical trial data] to patients we see every day in clinic?” Dr Gregory Piazza and Dr Barnes analyse real-world VTE data, highlighting shared decision-making for determining the most suitable anticoagulation therapy for a person with VTE.

Episode 2: The treatment landscape for CAT

“If there is a compliance and an adherence issue, it’s with the injectables” Dr Alok Khorana joins Dr Barnes to discuss the real-world versus clinical trial evidence of adherence to injectables, including the importance of taking a patient’s values and preferences into account when making treatment decisions.